title: Higher levels of neutralizing antibodies against KSHV in KS patients compared to asymptomatic individuals from Zambia.
abstract: Kaposi sarcoma-associated herpesvirus (KSHV) is the etiologic agent for Kaposi Sarcoma (KS), the most common cancer diagnosed in HIV- infected patients. The role of neutralizing antibodies in KS pathogenesis and in KSHV infected individuals is not clearly understood. The goal of this study was to investigate and compare the prevalence and titers of neutralizing antibodies in plasma samples from KS patients and KSHV infected asymptomatic individuals from Zambia, a KS endemic region in sub-Saharan Africa. Plasma samples (N = 267) consisting of KS patients (group 1) and asymptomatic individuals (group 2) were collected from Lusaka, Zambia. A flow cytometry based quantitative neutralization assay utilizing recombinant KSHV expressing GFP was used to detect KSHV neutralizing antibodies. Our results show that the overall prevalence of neutralizing antibodies in KS patients (group 1) was 66.7% which was significantly higher than the prevalence of 6.5% present in KSHV infected asymptomatic individuals (group 2). Total antibody titers as well as neutralizing antibodies titers were found to be significantly higher among KS patients. It is likely that higher neutralizing antibodies prevalence and titers in KS patients result from higher levels of antigenic stimulation over time. This study is first to compare prevalence and titers of neutralizing antibodies in participants with and without disease from a KSHV endemic region.
authors: Nebraska Center for Virology and the School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, Nebraska, United States of America.
authors: Pankaj
authors: P
authors: Kumar
authors: Nithal Y
authors: NY
authors: Kuwa
authors: Veenu
authors: V
authors: Minhas
authors: Clemence
authors: C
authors: Marimo
authors: Danielle M
authors: DM
authors: Shea
authors: Chipepo
authors: C
authors: Kankasa
authors: Charles
authors: C
authors: Wood
mesh_terms: D000328:Adult; D057134:Antibodies, Neutralizing / Q000097:blood* / Q000276:immunology*; D058070:Asymptomatic Diseases; D019353:Endemic Diseases; D005260:Female; D057809:HEK293 Cells; D019288:Herpesvirus 8, Human / Q000276:immunology*; D006801:Humans; D008297:Male; D012514:Sarcoma, Kaposi / Q000097:blood* / Q000453:epidemiology / Q000821:virology*; D015024:Zambia / Q000453:epidemiology
chemical_list: D057134:Antibodies, Neutralizing
references: J Infect Dis. 2004 Jun 1;189(11):2016-22
references: 15143468
references: Br J Cancer. 1998 Dec;78(11):1521-8
references: 9836488
references: Am J Epidemiol. 2011 May 1;173(9):1085-92
references: 21447476
references: Blood. 1995 Aug 15;86(4):1276-80
references: 7632932
references: AIDS. 1996 Feb;10(2):175-80
references: 8838705
references: J Virol. 2009 Oct;83(19):10269-74
references: 19640996
references: N Engl J Med. 1995 May 4;332(18):1186-91
references: 7700311
references: Clin Vaccine Immunol. 2008 Aug;15(8):1259-64
references: 18508931
references: Int J Cancer. 1998 Oct 23;79(5):481-6
references: 9761116
references: J Infect Dis. 1999 Oct;180(4):1010-7
references: 10479125
references: PLoS One. 2009;4(1):e4222
references: 19156206
references: Science. 1994 Dec 16;266(5192):1865-9
references: 7997879
references: J Med Virol. 2004 Oct;74(2):202-6
references: 15332267
references: Lancet. 1995 Sep 23;346(8978):799-802
references: 7674745
references: Virology. 2004 Aug 1;325(2):225-40
references: 15246263
references: Cytokine Growth Factor Rev. 1998 Mar;9(1):63-83
references: 9720757
references: Br J Cancer. 2006 May 22;94(10):1504-9
references: 16705315
references: Int J Cancer. 2003 Jan 10;103(2):226-32
references: 12455037
references: AIDS. 2000 Sep 29;14(14):2109-16
references: 11061651
references: HIV Med. 2006 Sep;7(6):369-77
references: 16903981
references: J Virol. 2009 Jan;83(2):757-69
references: 18987148
references: Int J Cancer. 1998 Aug 12;77(4):543-8
references: 9679756
references: J Infect Dis. 1998 Dec;178(6):1787-90
references: 9815235
references: Blood. 1998 Jul 1;92(1):53-8
references: 9639499
references: J Med Virol. 2011 Mar;83(3):384-90
references: 21264857
references: J Am Acad Dermatol. 1990 Jun;22(6 Pt 2):1237-50
references: 2193952
references: J Am Acad Dermatol. 2008 Aug;59(2):179-206; quiz 207-8
references: 18638627